%0 Journal Article
%T Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)
%A Fangrui Wu
%A Fengju Chen
%A Guohui Wang
%A Jingyu Wu
%A Lianghao Lu
%A Michele Redell
%A Padmini Narayanan
%A Qianxing Mo
%A Yefei Wen
%A Yongcheng Song
%A Yuan Yao
%J Theranostics
%D 2018
%I Ivyspring International Publisher
%R 10.7150/thno.22800
%X Acute myeloid leukemia (AML) is a major blood cancer with poor prognosis. New therapies are needed to target oncogene-driven leukemia stem cells, which account for relapse and resistance. Chromosome translocation t(8;21), which produces RUNX1-ETO (R-E) fusion oncoprotein, is found in ~13% AML. R-E dominance negatively inhibits global gene expression regulated by RUNX1, a master transcription factor for hematopoiesis, causing increased self-renewal and blocked cell differentiation of hematopoietic progenitor cells, and eventually leukemia initiation.
%K Acute myeloid leukemia
%K chromosome translocation t(8
%K 21)
%K RUNX1-ETO
%K Glucocorticoid
%K Glucocorticoid receptor
%K Targeted therapy
%U http://www.thno.org/v08p2189.htm